Is This the Right Drug or the Dose for the Management of Onychomycosis?

Purva Thatai, Bharti Sapra*
Department of Pharmaceutical Sciences, Punjabi University, Patiala, India

Keywords: Dermatophytes; Onychomycosis; Fungistatic effect

Introduction

Onychomycosis is a fungal infection of the toenails and fingernails that results in thickening, discoloration, splitting as well as lifting of the nails from the nail bed. It affects 14% of the total world population, with more prevalence in elders and diabetics. Both dermatophytes (Trichophyton rubrum or T. mentagrophytes) and nondermatophytes (Scopulariopsis brevicaulis, Aspergillus spp, Fusarium spp, and sometimes Candida spp) have been identified as etiologic agents of onychomycosis. The treatment of onychomycosis is known to be challenging since it is a chronic condition, difficult to eradicate and tends to relapse [1]. The pharmacotherapy of onychomycosis involves prolonged systemic or oral antifungal therapy due to slow turnover rate of nail as well as limited blood circulation into the affected nail bed. However, complete cure that involves a clinical cure (normal nail morphology) and mycological cure (both negative microscopy and dermatophyte culture), is often unattainable. In recent years the development of antifungal drugs of second generation (fluconazole, itraconazole, and terbinafine) has produced notable, long-term cure rates with shorter treatment period and improved safety profiles as compared to the first generation antifungal agents. However, different dosage regimens of various antifungal agents have been used by various researchers in clinical trials in order to ensure the complete eradication of the fungal infection in a shorter period with better efficacy.

Antimycotics Used to Treat Onychomycosis

The attempts have been made since ages to cure onychomycosis. However, there have been a number of failures in treatment and development programs. The prerequisite of treatment of the disease is the penetration of drug to the infected nail bed; however, low permeation rate of drugs necessitates prolonged treatment times.

First generation oral antifungals

Griseofulvin: Griseofulvin has been in the market since last 40 years and represented a promising advancement in antifungal therapy. The drug was found to be active against growing hyphae. In addition, it inhibits nucleic acid synthesis, and arrests fungal cell mitosis in metaphase. However, its effectiveness in onychomycosis is questionable, because of its limited spectrum of activity against dermatophytes only and hence, a longer duration of therapy is required [2]. The fungistatic effect of griseofulvin is believed to be confined in the nail matrix only, hence, only the newly grown nail plate is cleared of the invading fungus. Due to poor retention of the drug in the nail plate after the cessation of oral dosing, a continuous therapy for a prolonged period of time becomes a requisite to maintain the therapeutic level of drug in the nail plate, owing to slow growth of the nail. The prolonged therapy is generally associated with a number of side effects resulting in poor patient compliance, which in turn leads to meager success rate and recurrence of infection [3]. Additionally, the cost of prolonged daily therapy with griseofulvin could be unaffordable.

Ketoconazole: Ketoconazole was the first orally active imidazole having a broad spectrum of activity against dermatophytes as well as non-dermatophytes. However, the prolonged oral delivery of ketoconazole is associated with a number of adverse effects including hypersensitivity reactions, nausea, vomiting, headache, abdominal pain, pruritus, and fever and drug interactions. The major drug interactions of ketoconazole were observed with the drugs metabolized by the cytochrome P-450 system, as well as with certain other drugs (warfarin, rifampin, isoniazid, cyclosporine, terfenadine, cisapride) [4]. Moreover, the prolonged ketoconazole therapy necessitates regular liver function testing that was due to the hepatotoxicity [5]. Hence, the use of ketoconazole for an extended period was restricted prior to the invention of new antifungal agents because of its poor safety and efficacy data.

Second generation oral antifungals

The second generation of antifungals includes azoles and its derivatives (fluconazole, itraconazole), and allylamine (terbinafine). The azoles and allylamines block the pathway of ergosterol synthesis at different points, which results in difference of implications for efficacy and side effects these drugs Figure 1 and Table 1 summarizes.

Figure 1: Mechanism of action of second generation anti-fungals.

*Corresponding author: Bharti Sapra, Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, 147002, Punjab, India, Tel: +91-09501019661; E-mail: bhartijatin2000@yahoo.co.in

Received January 21, 2017; Accepted February 11, 2017; Published March 06, 2017

Citation: Thatai P, Sapra B (2017) Is This the Right Drug or the Dose for the Management of Onychomycosis? J Cosmo Trichol 3: 117. doi:10.4172/2471-9323.1000117

Copyright: © 2017 Thatai P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Variable | Griseofulvin | Ketoconazole | Fluconazole | Itraconazole | Terbinafine
--- | --- | --- | --- | --- | ---
Route of administration | Oral | Oral / Topical | Oral or intravenous | Oral | Oral / Topical
Associated Problems | Tolerance, longer treatment length | Toxicity, Interactions | Interactions, Microbe resistance | Interactions | Adverse Effects
Affinity for keratin | Low | High | High | High | High
Indicated for skin infection | + | + | + | + | +
Indicated for nail infection | – | – | + | + | +
Commercial Dosage Forms Available | Suspension (125 mg / 5ml); Tablet (125 mg, 250 mg, 500 mg) | Cream (2%), Gel (2%), Shampoo (2%), Tablet (250mg) | Suspension (50 mg/5ml, 200 mg/5ml), Injectable (200 mg/100ml, 400 mg/200ml), Tablet (50 mg, 100 mg, 150 mg, 200 mg) | Capsules (100 mg), Tablet (200 mg), Solution (10 mg/ml) | Tablet (250 mg), Gel (1%), Cream (1%), Solution (1%), Spray (1%)

Table 1: Key characteristics of oral antifungal agents.

| Nature of study | No. of subjects | Stage of Onychomycosis | Dosage Regimen | Follow up period | Observation | Remarks | Ref. |
| --- | --- | --- | --- | --- | --- | --- | --- |
| * | 20 | Severe | 150 mg once a week for 9.3 months | 6 months | 92% of toenails were clinically and mycologically free. | Effective in the long-term therapy of onychomycosis. | [10] |
| Open-labelled, non-comparative study | 16 | Finger and toenail | 150 mg daily for 6 months | * | No adverse effect was observed. | Safe and efficacious, however, further studies are needed to determine a cost-effective dosing regimen. | [11] |
| Pilot study | 11 | Toenail of fingernail | Group I: Eight patients received 300 mg once weekly
Group II: one patient received 200 mg once weekly
Group III: two patients received 100 or 200 mg of fluconazole every other day | * | 6 patients with toenails involved were clinically cured after a mean treatment duration of 6 months, and all five patients with fingernails involved were cured after 3.7 months. | Intermittent fluconazole, taken once weekly or on alternate days, is a well-tolerated and efficacious method to treat onychomycosis. | [12] |
| An open-label, noncomparative, multicenter study | 114 | Toenail | 150-mg fluconazole once per week | 1, 3 and 6 months | After 6 months Clinical cure: 54%
Mycological cure: 76%. | Well tolerated with adverse events of mild-to-moderate severity. | [13] |
| A placebo-controlled, randomized, double-blind trial | 362 | Finger or toenail | 150, 300, and 450 mg once weekly for 6 months | * | Clinical cure amongst all the doses was between 80 and 90%
Mycological cure was 53, 59, and 61% for 150, 300 and 450 mg dose, respectively. | All the regimens were Well tolerated and incidence and severity of adverse events were similar for fluconazole- and placebo-treated patients. | [14] |
| * | 50 | Finger and toenail | 400 mg once weekly for 12 months | * | 21.2% patients achieved mycological eradication, yet no clinical cure was obtained, while, 12.1% patients showed mycological and clinical failure. | High efficacy, good tolerance and low therapy costs. | [15] |

* Not mentioned

Table 2: Clinical studies of fluconazole carried out by various researchers.

the comparison of some key characteristics of the first generation (griseofulvin and ketoconazole) and second generation (itraconazole, fluconazole, terbinafine) antifungal drugs [6].

Fluconazole: Fluconazole, a water soluble bis-triazole drug, is available commercially in oral and intravenous dosage forms. The drug has high bioavailability (~90%) which is due to the physiochemical properties of the drug like low molecular weight and high water solubility. The drug is shown to have high affinity towards keratin which was evidenced by its detection in skin within 3 h of initial therapy. In case of nails, an investigation found the concentration of fluconazole to be 1.3 and 1.8 μg/g on 1st and 14th day of treatment (50 mg per day), respectively in healthy male volunteers [7]. In a long term study (6 months) on healthy and diseased nails, the drug was found to retain in the nail plate (2 μg/g) for around 5 months after discontinuation of therapy [8].

Gupta et al. (2013) compared databases of different researchers to study the relationships between fluconazole doses, cure rates and duration of therapy. The findings of the analysis concluded that longer treatments, but not higher weekly fluconazole doses, results in better cure rates for toenail, and possibly fingernail, onychomycosis. The lowest dose of 150 mg weekly for more than 6 months was recommended for onychomycosis [9]. Table 2 summarizes clinical studies carried out by various researchers in order to optimize the dosage regimen of fluconazole.

Itraconazole: Itraconazole, a triazole derivative was approved by FDA in 1995 for the management of onychomycosis and is available as capsule and oral solution. The broad spectrum activity, high affinity for keratin and pharmacokinetic profile of itraconazole is accountable for its high efficacy as compared to other antifungals. Although, initially the drug was indicated for the treatment of onychomycosis due to dermatophytes, it has also found to be effective against non-dermatophytes. It is rapidly absorbed, attains the peak level within 4h and undergoes extensive metabolism by the liver. The observed absolute oral bioavailability of itraconazole is about 56% [7]. The drug reaches the nail plate within 24 h of administration and can be observed in the distal part of the nail plate even after one month of initiation of therapy.
[10-16]. The diffusion of the drug into the distal part of the nail occurs via nail bed that is further confirmed due to the presence of two fold-higher drug concentration in subungual nail material than in distal nail clippings of a patient treated for one month. Itraconazole is found to be present in the nail for longer period of time than fluconazole or terbinafine and could be detected even after 9 months of termination of therapy [6]. The oral therapies have usually been recommended as a continuous-dosing regimen for the treatment of onychomycosis. For example, primarily the suggested dose of itraconazole for the management of onychomycosis was 200 mg per day for 3 months. Pharmacokinetic data of itraconazole in the nail bed observed from this study was further utilized to develop an alternative optimal dosage regimen for the treatment of onychomycosis. The treatment course with itraconazole was suggested to be curtailed to only one week interval owing to its rapid penetration and protracted persistence in the nail even after the discontinuation of drug. Moreover, the shorter dosing regimens have merits in terms of being cost effective and higher patient compliance as compared with longer regimens. Therefore, itraconazole has been assessed in intermittent dosing or “pulse therapy” regimens. Pulse therapy with itraconazole embodies dosing for 1 week (pulse) per month for a set number of months [17]. The instances of regimens that have been investigated for safety and efficacy in randomized trials included a three and a four pulse regimen with doses of 200 mg of itraconazole twice daily [18,19] and a two pulse regimen with 200 mg of itraconazole twice daily [17,20-22]. Data from clinical practice and clinical trials indicate that the 1-week pulse regimen of itraconazole is well tolerated and associated with a favorable safety profile [23]. This might lead to the conclusion of using 200 mg one week pulse regimen as efficacious and safer dosage regimen. Table 3 summarizes the various clinical studies involving different regimens of itraconazole and the cure rate obtained.

**Terbinafine**: Terbinafine is an allylamine derivative reported to have a broad spectrum activity against dermatophytes, certain dimorphic fungi, yeasts and moulds, but has less activity against C. albicans infections. Being lipophilic in nature it gets distributed in tissues like skin, fat, and nails. The drug showed high cure rates (80%) with 20% relapse rate and minimal side effects when administered in dermatophytic infections of the toenails for 12 months. In subsequent trials, concise treatment times were evaluated as the mycologic cure was observed early in these studies. In an investigation, 250 mg per day of terbinafine or placebo was given to 85 patients with mycologically proven dermatophyte onychomycosis of the toenails (75 patients) or fingernails (10 patients) for the period of 12 weeks, with long term follow up till 36 weeks. The observations revealed the mycological cure rate of 82% and 12% at follow up among terbinafine treated and placebo treated patients, respectively. The clinical cure rates of fingernail infections were observed to be 71% in terbinafine treated patients at follow up. The findings demonstrated the statistically significant advantage of terbinafine over placebo [24,25].

Subsequently, various studies are summarized in Table 4 that were conducted varying the dosage regimens and treatment periods in order to obtain higher clinical and mycological cure rate. From the above studies [26-30], it could be inferred that pulse therapy was equally efficacious as that of the continuous therapy and in certain cases it was even better. Thus, the former regimen can be preferred owing to the cost effectiveness of the treatment.

Some investigations were carried out in order to compare different available antifungals so as to determine the most reliable and efficacious antifungal agent. Table 5 enlist the comparison of clinical studies of antifungal agents [31-35]. From these findings, terbinafine was found to be more efficacious than other antifungals for the management of onychomycosis.

### Topical therapy

The cure of onychomycosis is known to be strenuous since it is chronic, difficult to obliterate and tends to relapse [36-39]. The pharmacotherapy for onychomycosis widely involves the oral antifungals because their systemic or circulatory distribution allows them to penetrate the nail apparatus and the nail plate. Unfortunately, oral therapy is generally coupled with serious side effects, drug interactions, and high recurrence rates. Therefore, topical therapy is an attractive option due to its non-

### Table 3: Clinical studies involving different regimens of Itraconazole

| Nature of study | No. of subjects | Site or Stage of Onychomycosis | Dosage Regimen | Follow up period | Observation | Remarks | Ref. |
|-----------------|-----------------|-------------------------------|----------------|-----------------|------------|--------|-----|
| Multicenter, randomized, double blind, placebo controlled | 73 | Fingernail | 200 mg twice daily, or placebo for the first week of each month for 2 consecutive months | 19 weeks | Clinical success: 77% in drug treated vs 0% in placebo treated patients. Mycological cure: 73% in drug treated vs 13% in placebo treated patients. | Short term pulse therapy is effective and well tolerated. | [17] |
| * | 50 | Toenail | 400 mg per day d given for 1 week each month for 3 to 4 months | Upto 1 year | Clinical Cure was 76 to 84%. Mycological Cure was 72 - 80 %. | Pulse therapy with Itraconazole is an effective and safe treatment option for onychomycosis as the drug persist in nail for a prolonged time even after the discontinuation of therapy. | [18] |
| Multicentre, Double blind, Parallel group study | 129 | Distal subungual onychomycosis of toenail | Group I: 200 mg daily for 3 months (continuous therapy); Group II: 400 mg daily 1 week per month for 3 months (pulse therapy) | 9 months | Clinical success: 69%, in Group I and 81% in Group II. Mycological cure: 66 and 69% in Group I and II, respectively. | Both regimens are effective, safe and well tolerated. | [19] |
| Multicenter, randomized, double blind, placebo controlled | 214 | Toenail | 200 mg capsules once daily for 12 weeks | 9 months | Clinical success: 65% in Itraconazole treated patients versus 3% of placebo treated patients Mycological cure: 54% in Itraconazole treated patients and 6% of placebo treated patients. | Continuous therapy of Itraconazole is highly effective, well-tolerated therapy for the management of toenail onychomycosis. | [24] |

*Not Mentioned*
invasiveness, localized effects and obliteration of systemic adverse events and drug interactions [40]. The primary drawback associated with the existing topical antifungal agent is their inability to penetrate into the nail plate resulting in poor mycological and complete cure rates. Hence, the ideal scenario would be to develop the topical agents that have an escalated nail plate penetration as compared to the existing drugs, as well as obviate the systemic uptake [41].

The conventional topical formulations such as creams or ointments are not suitable vehicles for transungual delivery because of the dissimilarity of nail keratin structure with that of the epidermis. Therefore, products specifically suggested for effective transungual therapy are nail lacquers. The primary drugs used as nail lacquers include ciclopirox (8%) and amorolfine (5%). After solvent evaporation, the drug in nail lacquer increases to about 35% after its application, that is significantly higher than the minimal inhibitory concentration (MIC) for T. rubrum, T. mentagrophytes and C. albicans [44]. The 8% concentration of drug in nail lacquer increases to about 35% after its application, that is significantly higher than the minimal inhibitory concentration (MIC) for T. rubrum, T. mentagrophytes and C. albicans [44]. The 8% concentration of drug in nail lacquer increases to about 35% after its application, that is significantly higher than the minimal inhibitory concentration (MIC) for T. rubrum, T. mentagrophytes and C. albicans [44]. The 8% concentration of drug in nail lacquer increases to about 35% after its application, that is significantly higher than the minimal inhibitory concentration (MIC) for T. rubrum, T. mentagrophytes and C. albicans [44]. The 8% concentration of drug in nail lacquer increases to about 35% after its application, that is significantly higher than the minimal inhibitory concentration (MIC) for T. rubrum, T. mentagrophytes and C. albicans [44]. The 8% concentration of drug in nail lacquer increases to about 35% after its application, that is significantly higher than the minimal inhibitory concentration (MIC) for T. rubrum, T. mentagrophytes and C. albicans [44].

Ciclopirox: Ciclopirox, a hydroxy-pyridone derivative exhibits a broad spectrum antifungal activity. The drug has been under investigation since 1973, however, it is being used in the lacquer form since 1990s. In nail lacquer formulation, the drug is present as a free acid, while, in other formulations (cream, suspension, shampoo, gel, solution, powder, globules) it is present as ethanolamine salt and the former is known to be a more active form [42,43]. The 8% concentration of drug in nail lacquer increases to about 35% after its application, that is significantly higher than the minimal inhibitory concentration (MIC) for T. rubrum, T. mentagrophytes and C. albicans [44]. The drug is thought to act by chelating trivalent cations (Fe3+ and Al3+) which results in the inhibition of metal-dependent enzymes (cytochromes, catalases, peroxidases), that in turn reduced the transport of ions through pathogen cytoplasmic membranes as well as reduce nutrient intake. The clinical studies revealing the efficacy of 8% ciclopirox are enlisted in Table 6.

Amorolfine: Amorolfine is a morpholine derivative, reported to exhibit a broad spectrum fungicidal and fungistatic activity [45-49]. It acts by inhibiting ergosterol synthesis at two steps i.e by inhibiting delta-14 reductase and delta 7, 8-isomerase. The depletion of ergosterol affects the membrane synthesis of pathogen and causes

| Nature of study | No. of subjects | Site or Stage of Onychomycosis | Dosage Regimen | Follow up period | Observation | Remarks | Ref. |
|-----------------|-----------------|--------------------------------|----------------|------------------|------------|---------|------|
| Randomized      | 120             | Toenail                        | 250 mg per day for 24 weeks | Upto 48 weeks   | Cure rates of 40%, 71% and 79% were observed after 6, 12 and 24 weeks, respectively. | A treatment period of 12 weeks is sufficient. | [26] |
| *               | 65              | Distal subungual onychomycosis of the fingernails or toenails, | 250 mg daily for 48 weeks | 6 months | Mycological and clinical cure rates were 70% and 54% for C. albicans, and 85% and 63% for C. parapsilosis, respectively. In addition to dermatophytes, terbinafine is also effective against non-dermatophytes. | | [27] |
| Multicentre, randomized, double-blind, | 118 | Toenail | 250 mg per day or placebo for 12 weeks | 48 weeks | Mycological cure: 94%. Terbinafine is effective against non-dermatophytes. | | [28] |
| Double blind    | 148             | Finger and toenail             | Group I: 250 mg per day for 6 weeks, Group II: 250 mg per day for 12 weeks. | 36 weeks | Clinical cure: 45.9%. Mycological cure: 58.9%. | In toenail mycoses without visible matrix involvement, 6 weeks treatment of terbinafine is generally not sufficient, whereas, fingernail infections respond well to this short therapy. | [29] |
| Multicentre, randomized, double blind | 618 | Distal subungal | Group I: 250 mg daily for 3 months (continuous) Group II: 500 mg daily for 1 week per month for 3 months (pulse) | 18 months | Clinical cure: 44.6% and 29.3% in Group I and II, respectively. Mycoligic cure: 70.9% and 58.7% in Group I and II, respectively. | Continuous therapy is superior as compared to pulse-dose. | [30] |
| Open label, randomized | 504 | Toenail | 250 mg per day for 12 weeks with or without aggressive toenail debridement (at baseline and weeks 6, 12, and 24) | 48 weeks | Clinical cure: 41.3% Mycological cure: 64.0%. | Debridement showed no effect on mycologic outcomes or clinical effectiveness. | [31] |
| *               | 55              | Finger and toe nail            | 500 mg per day for 1 week, followed by a 3-week interval + Topical 1% terbinafine cream was applied daily | 1 year | Complete cure: 74.5%. Safe and cost effective regimen. | | [32] |
| Randomized      | 76              | Toenail                        | Group I: 250 mg daily for 12 weeks Group II: 3 pulses of terbinafine (each of 500 mg daily for a week) repeated every 4 weeks | 24 weeks | Clinical success: 86.8% in group I and 71.1% in Group II. Mycological cure: ~ 75%. | A pulse dosing schedule was as efficacious as in a continuous daily schedule. | [33] |

* Not mentioned

Table 4: various studies conducted varying the dosage regimens of Terbinafine.
Table 5: Comparison of clinical studies of different antifungal agents.

| Nature of study | No. of subjects | Site or Stage of Onychomycosis | Dosage Regimen | Follow up period | Observation | Remarks | Ref. |
|-----------------|-----------------|--------------------------------|----------------|-----------------|------------|---------|------|
| Double blind, randomized, comparative | 372 | Toenail | Group I: Terbinafine; 250 mg/day (Continuous) Group II: Itraconazole, 200 mg/day for 12 weeks | Clinical cure: 76.2% in Group I and 58.1% in Group II. Mycological Cure: 73% in Group I and 45.8% in group II. | Terbinafine is more efficacious as compared to itraconazole. | [34] |
| Double blind, randomized, multicenter, comparative | 137 | Toenail | Group I: Terbinafine (250 mg daily for 12 weeks) Group II: Fluconazole (150 mg once weekly for 12 weeks) Group III: Fluconazole (once weekly for 24 weeks) | Clinical cure: 67%, 21% and 32% in Group I, II and III, respectively. Mycological cure: 89%, 51% and 49%, in Group I, II and III, respectively. | Terbinafine is more effective than fluconazole. | [35] |
| Single blind, randomized, multicentre, comparative | 190 | Toenail | Group I: Itraconazole pulse (200 mg twice daily for 1 week) followed by terbinafine pulse (250 mg twice daily for 1 week) Group II: 3 or 4 pulses of terbinafine | Clinical cure: 56.0% and 38.9% in Group I and II, respectively. Mycological cure: 72.0% in Group I versus 48.9% in Group II. | Sequential pulse therapy with itraconazole and terbinafine more is effective and safe. | [36] |
| Double-blind, double-dummy study | 151 | Toenail | Group I: Terbinafine 250 mg/day for 12 or 16 weeks (continuous) Group II: Itraconazole 400 mg/day for 1 week in every 4 weeks for 12 or 16 weeks (intermittent) | Mycologic cure: 46% in Group I and 13% group II. Mycological Relapse rate: 23% and 53% in Group I and II, respectively. Clinical relapse rate: 21% and 48% in Group I and II, respectively. | Continuous terbinafine provided superior efficacy and lower rates of relapse as compared to intermittent itraconazole. | [37] |
| Open labeled, randomized, comparative | 50 | Distal subungual toenail onychomycosis | Group I: Itraconazole once weekly for 3 months Group II: 200 mg itraconazole twice daily during the first week of each month of 3 month of treatment period Group III: 250 mg per day terbinafine for 3 months | Clinical cure rates: 81.3%, 77.8% and 37.5% in Group I, II and III, respectively. Mycological cure: 75%, 61.1% and 31.2% in Group I, II and III, respectively. | Fluconazole was least effective. With regard to cost-effectiveness, side effects and the cure rates, terbinafine could be the drug of choice in the short-term treatment of toenail onychomycosis. | [38] |
| Long term Prospective | 73 | Toenail | Group I: Terbinafine 250 mg/day (continuous) Group II: Itraconazole 400 mg/day for 1 week per month | Relapse Rate: 11.9% in Group I and 35.7% in Group II. | Terbinafine provide better long-term success than itraconazole. | [39] |

* Not mentioned

Table 6: Clinical studies investigation efficacy of ciclopirox.

| No. of subjects | Site or Stage of Onychomycosis | Dosage Regimen | Follow up period | Observation | Remarks | Ref. |
|-----------------|--------------------------------|----------------|-----------------|------------|---------|------|
| 460 | Mild to moderate toe onychomycosis | Group I: Ciclopirox once daily for 48 weeks Group II: Vehicle treated in US and other countries | 3 months | Mycological cure: ~ 32% in Group I and ~ 10% in Group II in US. In the non-US studies, the mycologic cure rates ranged from 46.7% to 85.7%. | Excellent safety profile; a treatment choice with a favorable benefit-to-risk ratio. | [45] |
| 460 | Affected nail area between 20% and 65% | Group I: Ciclopirox once daily for 48 weeks Group II: Vehicle | 3 months | Mycologic cure: 34% in Group I and 10% in Group II. Clinical cure: 8% in Group I and 1% in Group II. | Safe and effective. | [46] |
| 215 | Finger and toenail onychomycosis with diabetes | Once daily for 6 months | Ciclopirox nail lacquer reduced the mean affected nail area from 64.3% at baseline to 41.2% at 3 months and 25.7% at 6 months. | Safe and effective for the topical treatment of onychomycosis in patients with diabetes. | [47] |
| 49 | Distal subungual onychomycosis with diabetes | Once daily for 48 weeks | Clinical cure: 63.4% Mycological cure: 54.3 | Safe and effective treatment for distal subungual onychomycosis in patients with diabetes mellitus. | [48] |
| 40 | Distal and lateral subungual and lateral subungual toenail onychomycosis | Once daily for 9 months | 22% of the patients had complete cure | Low cure rate, can be used in patients who would not or cannot tolerate oral therapy. | [49] |
non-typical spherical sterols to accumulate in the fungal cytoplasmic membranes [50] which will in-turn affect the synthesis of membrane. The pharmacokinetic properties of the drug results in high penetration through the nail plate with minimal systemic absorption. Because of the solvent evaporation, the concentration of amorolfine increases from 5% to 27% [51]. Because of the pharmacokinetic profile of amorolfine, the drug has good penetration through the nail to the nail bed with minimal systemic absorption. Table 7 summarizes the clinical trials investigating the safety and efficacy of amorolfine in case of onychomycosis.

The findings obtained by different researchers revealed that no significant difference was obtained in cure rates with the application of once weekly or twice weekly of the nail lacquer. Therefore, once weekly use of nail lacquer containing 5% amorolfine can be preferred owing to patient compliance as well as cost effectiveness.

**Combination therapy**

The monotherapy is undoubtedly efficacious in short term; however, a complete and long lasting cure is often unattainable. In those cases, combination therapy has been found to be promising in ameliorating the overall cure rate of onychomycosis [52-55]. The use of combination approach and the application of antifungal drug synergy is a well-known concept in mycology. The combination of two or more drugs can result in augmented efficacy, rapidity of effects, a broader spectrum of activity and improved patient tolerability [55-59]. The benefits of combination therapy were first shown with griseofulvin as the standard therapy for the treatment of onychomycosis (due to dermatophytes) for the last 30 years. More recently, combinations of newer generation of drugs have been shown to have greater efficacy than griseofulvin (Table 8).

**Newer topical solutions**

There have been a number of unsuccessful development programs over the past decade as researchers endeavored to formulate antifungals that manifested in vitro activity against the common pathogens causing onychomycosis [60-63]. The discovery of new chemical entities exhibiting a broad spectrum of activity against multiple relevant fungal pathogens has led to progressive development of the dosage form and formulation for the treatment of different fungal diseases including onychomycosis [64,65].

The newer antifungal agents among azoles are efinaconazole, luliconazole, albaconazole, posaconazole and revuconazole, among benzoxaboroles is tevaborole and among allyl amines are NB-002 and NB-00X. Few amongst them are already commercially available, however, few of them are in different clinical phases.

**Efinaconazole:** Efinaconazole (Jublia® and Clenafin®) is an emerging antifungal therapy for the topical treatment of onychomycosis. Efinaconazole is an inhibitor of sterol 14a-demethylase and possess broad spectrum antifungal activity against dermatophytes, yeasts and non-dermatophyte molds. It is approved for use in Canada and the USA as a 10% topical solution for the treatment of onychomycosis [66,67].

The physicochemical properties and antifungal activity of drug and the nature of the vehicle are believed to contribute in favorable therapeutic outcomes of onychomycosis. Efinaconazole (10%) solution is found to be significantly more active than amorolfine and ciclopirox lacquers against dermatophytes in an in vivo guinea pig model. The keratin-bound efinaconazole was observed to release more rapidly after repeated washings (85.7% bound; 46% released) as compared to amorolfine (98.1% bound, 6.9% released) and ciclopirox (99.3% bound, 2.4% released) due to its lower affinity towards keratin [67]. The commercial formulation of the drug (solution) comprises of alcohol, lipophilic esters, and cyclomethicone. These components help to create a low surface tension which seems to be ideal for application to the surface of dry nail plate [68,69]. Unlike previous lacquer-based treatments, such as ciclopirox (8%), efinaconazole (10%) solution is effective without concomitant nail debridement between the applications. The studies, including investigation of efinaconazole 10% solution are summarized in Table 9.

**Luliconazole:** Luliconazole is a topical imidazole that has been tested in Phase I/II clinical trials. It is approved for the treatment of dermatomycoses in Japan [70]. A new set of clinical trials has been initiated to investigate luliconazole for the treatment of onychomycosis.

| No. of subjects | Site or Stage of Onychomycosis | Dosage Regimen | Follow up period | Observation | Remarks | Ref. |
|-----------------|--------------------------------|----------------|-----------------|-------------|---------|------|
| 554             | Finger and Toenails            | Group I: Twice weekly for 6 months Group II: Once weekly for 6 months | 3 months | Clinical cure: 52% and 46.1% in Group I and II, respectively. Mycological cure: 79.2 and 77.2 in Group I and II, respectively. | No statistically significant difference between the two groups. | [52] |
| 157             | More than 80% of the surface area of the nail affected | Group I: 2% amorolfine once weekly for 6 months Group II: 5% amorolfine once weekly for 6 months | 3 months | % Cure: 12% and 38% in Group I and II, respectively. | 5 % nail lacquer is significantly more effective than 2% of nail lacquer. | [53] |
| 727             | Finger or toenail              | Group I: 2% amorolfine once weekly for 6 months Group II: 2% amorolfine twice weekly for 6 months Group III: 5% amorolfine once weekly for 6 months Group IV: 5% amorolfine twice weekly for 6 months | 3 months | % Cure achieved: 16.3%, 35.8%, 45.6% and 51.8% in Group I, II, III and IV, respectively. | Amorolfine in the form of a 5% lacquer administered either once or twice weekly proved more effective. | [54] |
| 456             | Finger and toenails            | Group I: 5% amorolfine once weekly for 6 months Group I: 5% amorolfine twice weekly for 6 months | 3 months | Overall cure rate: 46% and 54.2% in Group I and II, respectively. Mycological cure rate: 70.6 and 76.1% in Group I and II, respectively. | No significant difference in cure rates. | [55] |

Table 7: Clinical trials investigating the safety and efficacy of amorolfine
| Combination                        | No. of subjects | Site or Stage of Onychomycosis | Dosage Regimen                                                                 | Follow up period | Observation                                                                 | Remarks                                                                 | Ref. |
|-----------------------------------|----------------|--------------------------------|-------------------------------------------------------------------------------|-----------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------|------|
| Topical tioconazole and oral Griseofulvin | 10             | Toenail                        | Group I: 500mg griseofulvin twice daily for one year + Tioconazole (28%) solution to be applied twice daily  
Group II: 500mg griseofulvin twice daily for one year + Placebo solution to be applied twice daily | Complete clinical cure: 69% and 41% in Group I and II, respectively. | Combination therapy produced a more rapid and complete response than when using the oral drug alone. | [56] |
| Oral Griseofulvin + oral Itraconazole | 90             | Toenail                        | Group I: Itraconazole (100mg per day)  
Group II: Griseofulvin (500 mg daily)  
Each group was divided into three subgroups that received different topical treatment: antifungal cream (tioconazole 1%), keratolytic cream (urea 40%), or placebo cream. | Complete cure: 93%, 83% and 41% in Group I, II and III, respectively at week 24. | The itraconazole group showed complete clearance in combination with tioconazole cream in 73.3% patients, in combination with keratolytic cream in 78.5% patients and in combination with placebo cream in 91.6% patients. The griseofulvin group showed complete clearance in combination with tioconazole cream in 48.1% patients, in combination with keratolytic cream in 42.8% patients, and in combination with placebo cream in 26.6% patients. | [57] |
| Topical amorolfine + oral terbinafine | 147            | Toenail                        | Group I: Oral terbinafine 250mg once daily for 6 months + 15 months of once-weekly topical amorolfine lacquer  
Group II: Oral terbinafine once daily for 12 months + 15 months of once-weekly topical amorolfine lacquer Group III: Terbinafine monotherapy for 12 weeks | Complete cure rate: 44%, 72.3% and 37.55 in Group I, II and III, respectively.  
Myological cure: 35%, 27.5% and 17.1% in Group I, II and III, respectively. | Combination therapy proved to be effective in severe onychomycosis. | [58] |
| Topical amorolfine + oral terbinafine | 147            | Toenail                        | Group I: Oral terbinafine 250mg once daily for 6 months + 15 months of once-weekly topical amorolfine lacquer  
Group II: Oral terbinafine once daily for 12 months + 15 months of once-weekly topical amorolfine lacquer Group III: Terbinafine monotherapy for 12 weeks | Complete cure rate: 44%, 72.3% and 37.55 in Group I, II and III, respectively.  
Myological cure: 35%, 27.5% and 17.1% in Group I, II and III, respectively. | Combination therapy regime with oral and systemic treatment was superior in efficacy as compare to monotherapy. | [59] |
| Topical amorolfine and oral Itraconazole | 131            | Toenail                        | Group I: Amorolfine 5% nail lacquer once weekly for 24 weeks + 200 mg Itraconazole once daily for 6 weeks  
Group II: amorolfine 5% nail lacquer once weekly for 24 weeks + 200 mg Itraconazole once daily for 12 weeks  
Group III: Itraconazole monotherapy for 12 weeks | Myological cure: 93.3%, 82.9% and 41.17% in Group I, II and III, respectively, in 12 weeks.  
Complete cure: 83.7%, 93.9% and 68.8% in Group I, II and III, respectively, in 24 weeks. | Combination therapy proved to be effective in severe onychomycosis. | [60] |
| Topical amorolfine + oral Itraconazole | 44 patients per group | Severe toenail onychomycosis | Group I: Amorolfine (5%) nail lacquer once weekly for 24 weeks + Itraconazole (2 capsules (100mg) once daily for 6 weeks  
Group II: Amorolfine (5%) nail lacquer once weekly for 24 weeks + Itraconazole (2 capsules (100mg) once daily for 12 weeks  
Group III: Monotherapy for Itraconazole for 12 weeks | Myologic cure: 93%, 83% and 41% in Group I, II and III, respectively at week 12.  
Complete cure: 84%, 94% and 69% in Group I, II and III, respectively at week 24. | Combination therapy was clinical effective and cost effective. | [61] |
| Topical amorolfine and oral Itraconazole | 91             | Fingernails                    | Group I: Itraconazole pulse therapy for 2 months and + amorolfine 5% solution nail lacquer for 6 months  
Group II: Monotherapy with three pulses of Itraconazole | Mylogic cure: 74% and 60% in Group I and II, respectively at 3 months.  
Complete cure: 93% and 81% in Group I and II, respectively at 9 months. | Combination therapy was more effective in case of severe onychomycosis than monotherapy. | [62] |
| Topical ciclopirox + oral terbinafine | 73             | Moderate to severe             | Group I: ciclopirox (8%) once daily for 48 weeks + 4 weeks of terbinafine 250 mg/day, followed by 4 weeks of rest (no terbinafine), then another 4 weeks of terbinafine 250 mg/day  
Group II: ciclopirox nail lacquer once daily for 48 weeks plus terbinafine 250 mg/day for 12 weeks  
Group III: terbinafine 250 mg/day for 12 weeks | Myologic cure: 66.7%, 70.4% and 56% in Group I, II and III, respectively.  
Complete cure: 40%, 33.3% and 34.8% in Group I, II and III, respectively. | Combination therapy may be an alternative regimen to continuous terbinafine in the treatment of moderate to severe onychomycosis. | [63] |
Oral terbinafine + topical ciclopirox or topical amorolfine 48 Finger and toenail Group I: Terbinafine 250 mg, one tablet twice daily for seven days every month (pulse therapy) Group II: oral terbinafine pulse therapy + topical ciclopirox laminate 8% to be applied once daily Group III: oral terbinafine pulse therapy plus topical amorolfine hydrochloride 5% to be applied once weekly for 4 months 36 weeks Clinical cure: 71.73, 82.60 and 73.91% patients in groups I, II and III, respectively. Mycological cure rate: 88.9, 88.9 and 85.7% in groups I, II and III, respectively. Combination therapy with topical ciclopirox or amorolfine did not show any significant difference in efficacy in comparison to monotherapy with oral terbinafine. [64]

Topical amorolfine and oral terbinafine 249 Toenail Group I: amorolfine hydrochloride 5% nail lacquer once weekly for 12 months + Terbinafine 250 mg once daily for 3 months Group II: Terbinafine alone once daily for 3 months 18 months Complete cure rate: 59.2 and 45% in Group I and II, respectively. Combination therapy enhanced clinical efficacy and was more cost-effective than terbinafine alone. [65]

*Not mentioned

Table 8: Clinical trials investigating efficacy of different combination of antifungal agents.

| No. of subjects | Site or Stage of Onychomycosis | Dosage Regimen | Follow up period | Observation | Remarks | Ref. |
|-----------------|--------------------------------|----------------|------------------|------------|---------|------|
| Study 1: N= 870; Study 2: N= 785 | Distal lateral subungual onychomycosis | Group I: Efinaconazole 10% solution once daily for 48 weeks Group II: Vehicle treated | 4 weeks | Mycologic cure: significantly greater (~ 53%) in Group I than Group II. Complete cure: ~16% in Group I and ~ 4% in Group II. | A viable alternative to oral treatment options. | [66] |
| 135 | Distal lateral subungual onychomycosis | Group I: Efinaconazole 10% solution (with or without semiocclusion), Group II: Efinaconazole 10% solution (without semiocclusion), Group III: efinaconazole 5% solution, Group IV: vehicle (once daily for 36 weeks) | 4 weeks | Mycologic cure: 83%, 87%, and 87% in Group I, II and III, respectively. Complete cure: was numerically higher in all active groups (16%-26%) compared with vehicle (9%). | Efinaconazole 10% solution (with or without semiocclusion) was more effective than vehicle. | [68] |
| 1,655 | Mild to moderate | Group I: Efinaconazole 10% solution once daily for 48 weeks Group II: Vehicle treated | * | Mycologic cure: 58.2% and 55.5% in mild and moderate onychomycosis, respectively, in Group I and 25.0% and 14.1%, respectively, in Group II. | A useful topical option in the treatment of mild-to-moderate onychomycosis. | [69] |

*Not mentioned

Table 9: Clinical studies including investigation of efinaconazole 10% solution.

In other markets also like USA. A pharmacokinetic study of luliconazole, in 24 participants with moderate-to-severe DLSO of both great toenails has recently been completed. The participants applied 20 mg/mL luliconazole, which is twice the recommended daily dose, for 29 days with a seven day follow-up. The pharmacokinetic assessment revealed that the systemic distribution of the drug was low (0.083-0.100 ng/mL) with the drug steady state achieved at eighth day. The drug was detected in the systemic circulation of several patients during the seven day follow-up period. The median concentration of luliconazole in the nail at this time point was 34.65 mg/g [71].

**Tevaborole:** Tevaborole, an oxaborole antifungal agent, is merchandised by Ancor Pharmaceuticals, CA, USA under the trade name "Kerydin". The drug got its FDA approval in 2014 for the treatment of fungal infection of the nail plate as well as of the nail bed. It acts by impeding protein synthesis of the pathogen by inhibiting the enzyme cytosolic leucyl-transfer RNA synthetase (LeuRS). The latter plays a significant role in protein synthesis pathway in the fungus. The inhibition of protein synthesis results in inhibition of cell growth and ultimately leads to eradication of fungus [72].

The topical use of tevaborole is preferred over the oral therapy so as to reduce the incidence of systemic side effects. The drug obliterates the use of debridement of the affected nail, which is often invasive and painful. The drug- drug interactions are to lesser extent in case of tevaborole as it has shown negligible inhibition of cytochrome P450 enzyme. Moreover, the safety and efficacy of the drug is found to be analogous to other available topical antifungal agents [73].

After obtaining the reasonable results from two clinical trials carried out by Ancor Pharmaceuticals, CA, USA; the findings from other multicentric analogous trials are also keenly anticipated to be successful. These clinical trials have imparted the advantage of assessment of systemic doses along with the different dosage forms apart from topical application. Some of them have accomplished clinical phases I and II [74]. The strong antifungal action of this drug is due to the presence of a very small element of boron in its structure. The drug possesses high patient compliance because of its topical application with negligible side effects. An extensive research is still required to ascertain the efficacy of this drug in comparison to other topical agents available.

**Other investigational drugs for onychomycosis**

The management of onychomycosis is a known to be a challenging endeavor owing to low cure rates and recurrence [75-80]. Due to this new molecules are gaining attraction of the researchers and subsequent clinical trials of these molecules indicate an equal investment for pharmaceutical companies. These drugs are under investigation for the treatment of onychomycosis, which vary widely from initial in vitro studies to gold-standard Phase III studies [81-84]. Table 10 enlists...
some these drugs which are being watch over by the clinicians for their efficacy and safety profile.

Conclusion

The stress has been laid upon by regulatory agencies on the importance of assessing the drug-dose response relationship and if possible, exposure-response relationship for the safety and effectiveness during drug development under clinical trials or even during post market surveillance/launch. The information collected from various clinical trials are defined and elaborated in the interest of patients. FDA and other regulatory agencies play a major role in clinical trial design and analysis. Various consonances are developed and set to encourage sharing of data in order to use correct drug and dose for the patients.

In case of onychomycosis, the major barriers affecting drug development for onychomycosis are the formidable barrier properties of the nail plate and an incomplete understanding of virulence factors of dermatophilic fungi, which impedes our understanding of novel drug targets. In order to achieve the complete cure and to shorten the treatment period so as to enhance the patient’s compliance, extensive research is going on and still requires more efforts in order to develop new drugs and to specify their dosage regimen.

References

1. Scher RK, Baran R (2003) Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 149: 5-9.
2. Speller DCE (1980) Antifungal chemotherapy. John Wiley & Sons Ltd., Chichester, England.
3. Elewski BE (1995) Clinical pearl: diagnosis of onychomycosis. J Am Acad Dermatol 32: 500-501.
4. Elewski BE, Hay RJ (1996) Update on the management of onychomycosis: highlights of the third annual international summit on cutaneous antifungal therapy. Clin Infect Dis 23: 305-313.
5. Janssen Pharmaceutica (1997) Ketoconazole package insert. Titusville, NJ: Janssen Pharmaceutica.
6. Elewski BE (1998) Onychomycosis: Pathogenesis, Diagnosis, and Management Clin Microbiol Rev 11: 415-429.
7. De Doncker P (1997) Pharmacokinetics of oral antifungal agents. Dermatol Ther 3: 46–57.
8. Fraki J, Heikillä HT, Kero MO, Kuukkanen K E, Oksman RO et al. (1991) Fluconazole in the treatment of onychomycosis: an open, non-comparative study with oral 150 mg fluconazole once weekly. Dermatology 2000 (symposium) Abstr. 14.
9. Gupta AK, Drummond-Main C, Paquet M (2013) Evidence-based optimal fluconazole dosing regimen for onychomycosis treatment. J Dermatol Treat 24: 75-80.
10. Kuukkanen K, Alava S (1991) Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treatment 3: 115-117.
11. Smith SW, Sealy DP, Schneider E, Lackland D (1995) An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. South Med J 88: 1217-1220.

12. Assaf RR, Elewski BE (1996) Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. J Am Acad Dermatol. 35: 216-219.
13. Fraki JE, Heikillä HT, Kero MO, Kuukkanen KE, Risto O, et al. (1997) An open-label, noncomparative, multicenter evaluation of fluconalone with or without urea nail pedestal for treatment of onychomycosis. Current Therapeutic Research 58: 481-491.
14. Scher RK, Breneman D, Rich P, Savin RC, Feingold DS, et al. (1998) Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 38: S77-S86.
15. Hryncwicz-Gwizdzt A, Plomer-Nezegoda E, Kalinowska K, Czarnecka A, Maj J, Jagielski T (2015) Efficacy of fluconazole at 400 mg weekly dose for the treatment of onychomycosis. Acta Derm Venereol 95: 251-252.
16. Matthieu L, De Doncker P, Cauwenbergh G, Woestenborghs R, van de Velde V, et al. (1997) Itraconazole penetrates the nail via the nail matrix and the nail bed: an investigation in onychomycosis. Clin Exp Dermatol 16: 374-376.
17. Odom RB, Aly R, Scher RK, Daniel III CR, Elewski BE, et al. (1997) A multicenter-placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J Am Acad Dermatol 36: 231-236.
18. De Doncker P, Decroix J, Pierard GE, Roelant D, Woestenborghs R, et al. (1996) Antifungal pulse therapy for onychomycosis: a pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 132: 34-41.
19. Havu V, Brandt H, Heikillä H, Hollmen A, Oksman R, et al. (1997) A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 136: 230-234.
20. Doncker PD, Gupta AK, Marynissen G, Stoffels F, Heremans A (1997) Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 37: 969-974.
21. Huang PH, Faller AS (2000) Itraconazole pulse therapy for dermatophyte onychomycosis in children. Arch Pediatr Adolesc Med 154: 614-618.
22. Firooz A, Khamesipour A, Dowlati Y (2003) Itraconazole pulse therapy improves the quality of life of patients with toenail onychomycosis. J Dermatol Treat 14: 95-98.
23. Gupta A, Lambert J, Revuz J, Shear N (2001) Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. Eur J Dermatol 11: 8-10.
24. Elewski BE, Scher RK, Aly R, Daniel R, Jones HE (1997) Double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of toenail onychomycosis. Cutis 59: 217-220.
25. Goodfield MJ (1992) Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol 122: 33-35.
26. van der Schroeef JG, Cirkel PK, Crijns MF, van Dijk TJ, Govaert FJ, et al. (1992) A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 126: 36-39.
27. Notting S, Brautigam M, Weidinger G (1994) Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 130: 16-21.
28. Ellis DH, Marley JE, Watson AB, Williams TG (1997) Significance of non-dermatophyte moulds and yeasts in onychomycosis. Dermatology 194: 40-42.
29. Tausch I, Bräutigam M, Weidinger G, Jones TC (1997) Evaluation of 6 weeks treatment of terbinafine in onychomycosis a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group. Br J Dermatol 136: 737-742.
30. Warshaw EM, Fett DD, Bloomfield HE, Grill JP, Nelson DB, et al. (2005) Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 53: 578-584.

31. Tavakkol A, Fellman S, Kianifard F (2006) Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in Onychomycosis-Concomitant Lamisil and Debriderment (IRON-CLAD), an open-label, randomized trial. Am J Geriatr Pharmacother 4: 113.

32. Takahata Y, Hiruma M, Shiraiki Y, Tokunaga Y, Sugita T, et al. (2009) Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500 mg day for a week). Mycoses 52: 72-76.

33. Yadav P, Singal A, Pandith D, Das S (2015) Comparative efficacy of continuous and pulse dose terbinafine regimens in toenail dermatophytosis: A randomized double-blind trial. Indian J Dermatol Venereol Leprol 81: 363-369.

34. De Backer M, De Vroey C, Lesaffre E, Scheyfs I, De Keyser P (1998) Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol 38: 557-63.

35. Havu V, Heikillä H, Kuckkanen K, Nuutilen M, Rantanen T (2000) A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) and fluconazole (Difucan) in the treatment of onychomycosis. Br J Dermatol 142: 97-102.

36. Gupta AK, Lynde CW, Konnikov N (2001) Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol 44: 485-491.

37. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, et al. (2002) Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 138: 353-357.

38. Arca E, Taştan HB, Akar A, Kurumlu Z, Gür AR (2002) An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. J Dermatol Treat 13: 39.

39. Piraccini BM, Sisti A, Tosti A (2010) Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 62: 411-414.

40. Thatai P, Sapra B (2014) Transungal delivery: deliberations and creeds. Int J Cosmo Trichol 3: 117. doi:10.4172/2471-9323.1000117

52. Reinel D, Clarke C (1992) Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 17: 44-49.

53. Lahuartana J (1992) Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 17: 41-43.

54. Zaug M, Bergstræsser (1992) Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview). Clin Exp Dermatol 17: 61-72.

55. Reinel D (1992) Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatology 184: 21-24.

56. Hay RJ, Clayton YM, Moore MK (1987) A comparison of itraconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol 12: 175-177.

57. Arenas R, Fernández G, Domínguez L (1991) Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antymycotic or keratolytic agent. Int J Dermatol 30: 586-589.

58. Baran R, Feulhade M, Combernale P, Datry A, Goettmann S, et al. (2000) A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol 142: 1177-1183.

59. Baran R (2001) Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol 145: 15-19.

60. Lecha M (2001) Amorolfine and itraconazole combination for severe toenail onychomycosis: results of an open randomized trial in Spain. Br J Dermatol 145: 21-26.

61. Lecha M, Alina M, Rodríguez JM, de Erenchun FR (2002) An open-label, multicenter study of the combination of amorolfine nail lacquer and oral itraconazole compared with oral itraconazole alone in the treatment of severe toenail onychomycosis. Curr Ther Res 63: 366-379.

62. Rigopoulos D, Katoulis AC, Ioannidies D, Georgala S, Kalogeromitros D, et al. (2003) A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br J Dermatol 149: 151-156.

63. Gupta AK (2005) Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol 4: 461-465.

64. Jaiswal A, Sharma RP, Garg AP (2007) An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol 73: 393-396.

65. Baran R, Sigurgeirsson B, de Berker D, Kaufmann R, Lecha M (2007) A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine combined with oral terbinafine alone in the treatment of onychomycosis with matrix involvement. Br J Dermatol 157: 149-157.

66. Elewski BE, Rich P, Pollak R, Pariser DM, Watanabe S, et al. (2013) Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol 68: 600-608.

67. Sugura K, Hosaka S, Tatsumi Y, Jo W (2013) Unique properties of efinaconazole 10% solution, a new topical treatment for onychomycosis. Poster presented at 71st Annual Meeting, American Academy of Dermatology, Miami Beach FL.

68. Tischen EH, Bucko AD, Oizumi N, Kawabata H, Olin JT, et al. (2013) Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study. J Drugs Dermatol 12: 186-192.

69. Rodrigues DA (2015) Efinaconazole Topical Solution, 10%, for the Treatment of Mild and Moderate Toenail Onychomycosis. J Clin Aesthet Dermatol 8: 24-29.

70. Uchida K, Nishiyama Y, Yamaguchi H (2004) In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother 10: 216-219.

71. Jones T, Tavakkol A (2013) Safety and tolerability of luliconazole solution 10-percent in patients with moderate to severe distal subungual onychomycosis. Antimicrob Agents Chemother 57: 2684-2689.
72. Baker SJ, Zhang YK, Akama T, Lau A, Zhou H, et al. (2006) Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis. J Med Chem 49: 4447-4450.

73. Gupta AK, Daigle D (2014) Potential role of Tavaborole for the treatment of onychomycosis. J Pharmacol Pharmacother 6: 236-239.

74. Sharma N, Sharma D (2015) An upcoming drug for onychomycosis: Tavaborole. Expert Rev Pharmacoeconomics Outcomes Res 15: 823-824.

75. van Rossem K, Lowe JA (2013) A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation. Clin Pharmacol 5: 23-31.

76. GlaxosmithKline. https://www.gskclinicalstudyregister.com/compounds/albaconazole/all/ (accessed on January 5, 2017).

77. Elewski BE, Pollak R, Ashton S, Rich P, Schlessinger J, et al. (2012) A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol 166: 389-398.

78. Moore JN, Healy JR, Kraft WK (2015) Pharmacologic and clinical evaluation of posaconazole. Expert Rev Clin Pharmacol 8: 321-334.

79. Gupta AK, Leonard C, Stoltz RR, Pierce PF, Conetta B, et al. (2005) A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 19: 437-443.

80. Yamaguchi H (2016) Potential of Ravuconazole and its Prodrugs as the New Oral Therapeutics for Onychomycosis. Med Mycol J 57: E93-E110.

81. Pannu J, McCarthy A, Martin A, Hamouda T, Ciotti S, et al. (2009) NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi, and candida albicans. Antimicrob Agents Chemother 53: 3273-3279.

82. Ghannoum M, Isham N, Herbert J, William H, Sam Y (2011) Activity of TDT 067 (Terbinafine in Transfersome) against Agents of Onychomycosis, Determined by Minimum Inhibitory and Fungicidal Concentrations. J Clin Microbiol 49: 1716-1720.

83. Sigurgeirsson B, Ghannoum M (2012) Therapeutic potential of TDT 067 (Terbinafine in Transfersome): a carrier-based dosage form of terbinafine for onychomycosis. Expert Opin Investig Drugs 21: 1549-1562.

84. Elewski BE, Ghannoum MA, Mayser P, Gupta AK, Korting HC, et al. (2011) Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J Eur Acad Dermatol Venereol 27: 287-294.